Author: Ezzat, Kariem; Zaghloul, Eman M.; EL Andaloussi, Samir; Lehto, Taavi; El-Sayed, Ramy; Magdy, Tarek; Smith, C.I. Edvard; Langel, Ülo
Title: Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions Cord-id: 9z7dtay9 Document date: 2012_8_20
ID: 9z7dtay9
Snippet: Cell-penetrating peptides (CPPs) are short cationic peptides that have been extensively studied as drug delivery vehicles for proteins, nucleic acids and nanoparticles. However, the formulation of CPP-based therapeutics into different pharmaceutical formulations and their stability in relevant biological environments have not been given the same attention. Here, we show that a newly developed CPP, PepFect 14 (PF14), forms non-covalent nanocomplexes with short interfering RNA (siRNA), which are a
Document: Cell-penetrating peptides (CPPs) are short cationic peptides that have been extensively studied as drug delivery vehicles for proteins, nucleic acids and nanoparticles. However, the formulation of CPP-based therapeutics into different pharmaceutical formulations and their stability in relevant biological environments have not been given the same attention. Here, we show that a newly developed CPP, PepFect 14 (PF14), forms non-covalent nanocomplexes with short interfering RNA (siRNA), which are able to elicit efficient RNA-interference (RNAi) response in different cell-lines. RNAi effect is obtained at low siRNA doses with a unique kinetic profile. Furthermore, the solid dispersion technique is utilized to formulate PF14/siRNA nanocomplexes into solid formulations that are as active as the freshly prepared nanocomplexes in solution. Importantly, the nanocomplexes are stable and active in mediating RNAi response after incubation with simulated gastric fluid (SGF) that is highly acidic. These results demonstrate the activity of PF14 in delivering and protecting siRNA in different pharmaceutical forms and biological environments.
Search related documents:
Co phrase search for related documents- absence presence and activity decrease: 1
- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and long period: 1, 2, 3, 4, 5
- absence presence and luciferase activity: 1, 2, 3, 4, 5
- absence presence and luciferase expression: 1
- absence presence and luciferase plasmid: 1
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- accession number and acute respiratory syndrome: 1, 2, 3
- accession number and luciferase expression: 1
- accession number and luciferase plasmid: 1
Co phrase search for related documents, hyperlinks ordered by date